Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.80 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.80 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.80 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.80 |
| ▸ | CHUK | O15111 | 1/20 | 0.80 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.80 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.80 |
| ▸ | RAF1 | P04049 | 1/20 | 0.80 |
| ▸ | BRAF | P15056 | 1/20 | 0.80 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.80 |
| ▸ | JAK1 | P23458 | 1/20 | 0.80 |
| ▸ | TYK2 | P29597 | 1/20 | 0.80 |
| ▸ | FLT3 | P36888 | 1/20 | 0.80 |
| ▸ | CLK1 | P49759 | 1/20 | 0.80 |
| ▸ | CLK2 | P49760 | 1/20 | 0.80 |
| ▸ | CLK3 | P49761 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538318 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Hydrochloric Acid SCHEMBL29370622 | 0.99 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| SCHEMBL10092297 | 0.90 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| SCHEMBL258277 | 0.89 | PIK3CA (0.82) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Pi-103 SCHEMBL29676244 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Pi-103 SCHEMBL30387212 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Pi-103 SCHEMBL29352781 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Pi-103 SCHEMBL258242 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Pi-103 SCHEMBL29929906 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB | |
| Pi-103 SCHEMBL29527390 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4706773-A2 | HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062712-A1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2026-01-22 | — | — | US | disclosed |
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2025-12-04 | — | — | US | disclosed |
| US-20250353916-A1 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4643874-A2 | MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY | Novartis AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-3393504-B1 | MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY | NOVARTIS AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-11365252-B2 | CD229 CAR T cells and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220153835-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3 | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220145326-A1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-05-05 | — | — | US | disclosed |
| EP-3280729-B1 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL | NOVARTIS AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-11312783-B2 | Antibody molecules to CD73 and uses thereof | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| EP-3967709-A1 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | Novartis AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| EP-3393504-A1 | MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY | Novartis AG (CH) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112741-A1 | MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY | NOVARTIS AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2012156379-A1 | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING | Universität Zürich (CH) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | LY96, CD74, EWSR1 | PIK3CA 2999/4885PIK3R1 228/4885MTOR 4781/4885 |
| US-20250353916-A1 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | CD2, FCGR3B, CD58 | PIK3CA 2700/4885PIK3R1 1774/4885MTOR 4690/4885 |
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | PTPRCAP, PTPRC, CD47 | PIK3CA 759/4885PIK3R1 198/4885MTOR 2307/4885 |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | PIK3CA 1849/4885PIK3R1 3457/4885MTOR 3367/4885 |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | IGSF11, IGLV6-57, CD2 | PIK3CA 4568/4885PIK3R1 1841/4885MTOR 4777/4885 |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | GSAP, BACE1, CD79B | PIK3CA 1688/4885PIK3R1 354/4885MTOR 1459/4885 |
| US-11365252-B2 | CD229 CAR T cells and methods of use thereof | CD2, CD2BP2, CD22 | PIK3CA 2629/4885PIK3R1 1090/4885MTOR 3025/4885 |
| US-20260062712-A1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | IGF2BP3, NUDT21, IGF2BP1 | PIK3CA 4271/4885PIK3R1 2638/4885MTOR 4612/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PIK3CA 264/4885PIK3R1 30/4885MTOR 147/4885 |
| US-11312783-B2 | Antibody molecules to CD73 and uses thereof | NT5E, ENTPD5, ENTPD1 | PIK3CA 1554/4885PIK3R1 3731/4885MTOR 4497/4885 |
| US-20220153835-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3 | CD47, CD2, NECTIN4 | PIK3CA 3309/4885PIK3R1 3096/4885MTOR 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.